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ABSTRACT 16 
Human colonic bacteria have an important impact on the biotransformation of 17 
flavonoid glycosides and their conversion can result in the formation of bioactive 18 
compounds. However, information about the microbial conversion of complex 19 
glycosylated flavonoids and the impact on the gut microbiota are still limited. In this 20 
study, in vitro fermentations with selected flavonoid O- and C-glycosides and three 21 
different fecal samples were performed. As a result, all flavonoid glycosides were 22 
metabolized via their aglycones yielding smaller substances. Main metabolites were 23 
3-(4-hydroxyphenyl)propionic acid, 3-phenylpropionic acid, and phenylacetic acid. 24 
Differences in the metabolite formation due to different time courses between the 25 
donors were determined. Therefore, from all fermentations, the ones with a specific 26 
donor were always slower resulting in a lower number of metabolites compared to the 27 
others. Exemplarily, tiliroside was totally degraded from 0h (105 ± 13.2 µM) within the 28 
first 24h, while in the fermentations with fecal samples from other donors, tiliroside 29 
(107 ± 52.7 µM at 0h) was not detected after 7h anymore. In general, fermentation 30 
rates of C-glycosides were slower compared to the fermentation rates of O-31 
glycosides. The O-glycoside tiliroside was degraded within 4h while the gut 32 
microbiota converted the C-glycoside vitexin within 13h. However, significant 33 
changes (p < 0.05) in the microbiota composition and short chain fatty acid levels as 34 
products of carbohydrate fermentation were not detected between incubations with 35 
different phenolic compounds. Therefore, microbiota diversity was not affected and a 36 
significant prebiotic effect of phenolic compounds cannot be assigned to flavonoid 37 
glycosides in food-relevant concentrations. 38 
 39 
 40 
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INTRODUCTION 45 
Flavonoids are a class of secondary plant metabolites which are found ubiquitously in 46 
the plant kingdom. Their chemical structure is characterized by two aromatic rings 47 
with at least one hydroxyl group.1 Flavonoids can be classified into several 48 
subgroups depending on the constitution of the heterocyclic C-ring.2 The chemical 49 
structures range from very simple substances to quite complex flavonoids consisting 50 
of several phenolic rings with a wide range of substituents. In plants, they are 51 
frequently conjugated with different small organic molecules (preferentially sugars 52 
and organic acids), affecting their water-solubility and functionality.3 Only 53 
occasionally they are present in plants as non-conjugated flavonoid aglycones.1 54 
Beside the very frequent O-glycosylation of flavonoids, flavonoid glycosides can also 55 
occur as C-glycosides.4 The most common sources of flavonoid C-glycosides are 56 
swiss chard, tomato, lemons, and some cereals such as maize, wheat, and rice.5, 6 57 
When consumed with plant foods, flavonoid glycosides are hypothesized to have 58 
health beneficial properties.7 Antimutagenic, anticarcinogenic, antiviral, antibacterial, 59 
and antiinflammatory properties have been described.8-11 Even though studies have 60 
mainly focused on the more common O-glycosides, it is assumed that C-glycosides 61 
would have better therapeutic properties due to their enhanced stability over the 62 
respective aglycone and O-glycosides.12 But especially for C-glycosides, more 63 
investigations on resorption, metabolism, and health beneficial effects have to be 64 
carried out.12 However, uptake/bioavailability of flavonoids is a crucial factor for 65 
potential bioactivities but this is still discussed controversially.13 It is highly dependent 66 
on the chemical structure and can therefore differ between different compounds. 67 
Moreover, bioactivity is influenced by the resorption rate, intestinal, and hepatic 68 
metabolism, and the subsequent distribution in the organism.14 Although different 69 
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pathways have been identified as being responsible for an enhanced resorption, it 70 
has to be concluded that in most cases resorption rates of intact flavonoids are not 71 
very high.15, 16 Consequently, the most important metabolic transformation of 72 
flavonoid glycosides takes place in the colon, where they undergo significant 73 
degradation by the gut microbiota.  74 
In the human colon more than 500 different bacterial species are found, whereby the 75 
composition of the microbiome is highly diverse and unique for every individual.7, 17 76 
Some of the bacterial species can catalyze (flavonoid) O- and C-deglycosylation, 77 
demethylation, dehydroxylation, ester cleavage, reduction of carbon-carbon double 78 
bond, isomerization, ring fission, and decarboxylation.18 However, not all bacteria are 79 
able to carry out every degradation step.19 For example, Enterococcus casseliflavus 80 
is only able to cleave and ferment the sugar moiety from different quercetin-O-81 
glycosides to short chain fatty acids (SCFA), while the aglycone is not degraded any 82 
further. In contrast, Eubacterium ramulus is capable of converting also the 83 
aglycone.20 Additionally, it is possible that some kind of cross-feeding effects due to 84 
the degradation of phenolic compounds occur. 21 It means that one strain gives good 85 
growth on the primary substrate such as the phenolic compound, which is 86 
metabolized to a product being a secondary substrate for another strain. This might 87 
enhance growth of further microorganisms and consequently influence composition 88 
of the colonic microbiota.22 89 
Although the structures of O- and C-glycosides are very different from a chemical 90 
point of view, the conversion of C-glucosides also showed a dependence on the 91 
presence of specific bacteria for degradation steps such as the cleavage of the C-C 92 
bond. For example, Eubacterium cellulosolvens is not able to deglycosylate the C-93 
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glycosides vitexin, while it is degradable by the intestinal Lachnospiraceae strain 94 
CG19-1.23  95 
When looking at fermentation experiments with fecal samples, it is possible to 96 
investigate at least two ways of action: On the one hand, the microbial transformation 97 
of flavonoids to bioactive products is of interest, whereas on the other hand, the 98 
influence of phenolic compounds and their metabolites on the composition of the gut 99 
microbiota is an important aspect, too (two-way phenolic - microbiota interaction).24 In 100 
general, combining metagenomics and metabolomics studies will help to better 101 
understand both types of interactions.25 However, information about the microbial 102 
transformation of more complex, highly glycosylated flavonoids, and evidence for 103 
their effect on the gut microbiota is still not sufficiently investigated. In some studies, 104 
it has been suggested that more complex polyphenols have an even higher effect on 105 
the microbiome than simple structures, because a larger variety of potentially 106 
bioactive metabolites can be formed.26 Therefore, such structures might also 107 
influence the diversity of the microbiota which is hypothesized to correlate with the 108 
health of an individual.27 109 
The aim of this study was to investigate the degradation of selected structurally 110 
related, highly glycosylated flavonoids and their influence on gut microbiota 111 
composition. Special focus was set on the comparative assessment of group specific 112 
differences between O- and C-glycosides. For this purpose, different in vitro 113 
fermentations with a limited number of human fecal samples were performed. 114 
Breakdown products were analyzed using HPLC-ESI-MS/MS analysis. To assess 115 
whether phenolic exposure influenced the microbiota, qPCR and Illumina sequencing 116 
were carried out to investigate potential compositional changes and SCFA production 117 
was determined to detect major functional changes. 118 
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MATERIAL AND METHODS 119 
Chemicals. Apigenin (AP, 4',5,7-trihydroxyflavone), kaempferol (K, 3,4',5,7-120 
tetrahydroxyflavone), kaempferol-3,4’-O-diglucoside-7-O-rhamnoside (K-DG-R), 121 
tiliroside (T, kaempferol-3-(6''-trans-p-coumaroyl)glucoside), vitexin (V, apigenin-8-C-122 
glucoside), and vitexin-2’’-O-rhamnoside (V-R) were purchased from Phytolab GmbH 123 
& Co. KG (Vestenbergsgreuth, Germany). Vitexin-2’’-O-glucoside (V-G), and vitexin-124 
2’’-O-xyloside (V-X) were isolated from swiss chard. The isolation method is 125 
described in the supplementary information.  126 
The chemical structures of the substrates used in this study are shown in Figure 1. 127 
All O-glycosides are based on the aglycone structure of kaempferol, whereas the 128 
structures of the C-glycosides are related to the aglycone apigenin. Both aglycones 129 
differ only in a hydroxyl group at C3-position of the basic skeleton. While tiliroside has 130 
only one sugar moiety being bound via a C-O bond at the C3-position and further 131 
esterification with p-coumaric acid, kaempferol-3,4’-O-diglucoside-7-O-rhamnoside is 132 
O-glycosylated with three sugar moieties at different positions. In contrast, vitexin is 133 
the simplest C-glucoside of apigenin, bound via a C-C bond at the C8-position. The 134 
different vitexin derivatives have a second sugar moiety at the C2’’-position. These 135 
bonds are C-O bonds. Consequently, the vitexin derivatives combine O- and C-136 
glycosidic bonds in one structure.  137 
In vitro degradation of phenolic substrates by fecal microbiota. This study was 138 
part of a set of experiments already described by Vollmer, et al. 28 in which three 139 
independent in vitro fermentations with fecal microbiota were performed. Fecal 140 
samples were donated by three different, healthy donors (donor A, B, and C) without 141 
a history of gastrointestinal disorders or any antibiotics consumption for at least three 142 
month prior to the fermentation experiment. Number of samples and fermentation 143 
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strategy were similar to related fermentation experiments already described in the 144 
literature.21, 29-31 The preparation of the fecal suspension was conducted according to 145 
Vollmer, Schröter, Esders, Farquharson, Neugart, Duncan, Schreiner, Louis, Maul 146 
and Rohn 28. In vitro fermentations were performed with eight different flavonoids in 147 
triplicate at an initial pH value of 6.5 in a final volume of 10 mL. Based on preliminary 148 
experiments with similar levels of carbon source(s) it was estimated that during 149 
fermentation the pH drops by 0.5-1 units. The volume of 10 mL consisted of 9.4 mL 150 
fermentation medium which contained several minerals, supplements, and 151 
carbohydrates to allow the gut bacteria to grow, 100 µL phenolic substrate (final 152 
concentration 200 µM, pre-dissolved in DMSO), 14 µL vitamin solution, and 500 µL 153 
freshly prepared fecal suspension (0.2% final fecal concentration). The preparation 154 
and ingredients of the fermentation media and vitamin solution are described 155 
elsewhere.28 156 
After adding the fecal suspension to the medium, the samples were incubated on a 157 
rotator (Stuart SB3, Bibby Scientific, Stone, UK) for 48 h at 37 °C and 25 rpm. Two 158 
aliquots of 750 µL were collected initially (0h), and after 3 h, 7 h, 24 h, and 48 h while 159 
flushing with CO2. One aliquot was frozen with liquid nitrogen and stored at -80 °C 160 
until HPLC-ESI-MS/MS analysis. The second aliquot was used for investigations of 161 
the microbiota and SCFA analyses. For that, the aliquot was separated into 162 
supernatant (SCFA analysis) and cell pellet (DNA analysis) by centrifuging.28 163 
Supernatant was stored at -20 °C until SCFA analysis and cell pellet dissolved in 164 
buffer at -80 °C. Incubation parameters of fecal fermentation and sample treatments 165 
were already described by Vollmer, Schröter, Esders, Farquharson, Neugart, 166 
Duncan, Schreiner, Louis, Maul and Rohn 28. 167 
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In addition to fecal suspensions with phenolic substrates, control samples for every 168 
fermentation without any substrates were conducted. This was done to determine the 169 
metabolite formation caused by compounds endogenously present in the fecal 170 
samples. For that, 100 µL DMSO were used instead of the substrate (‘control 171 
samples I’). For the estimation of the interactions of the substrates with the medium, 172 
100 µL substrate were combined with 9.9 mL medium and 14 µL vitamin solution and 173 
were treated the same way as the samples (‘control samples II’). 174 
The fermentation period in the present study was set to 48 h based on other in vitro 175 
fermentation experiments on phenolic compounds described in the literature. 19, 32-34 176 
Some of the fermentation experiments ended already after 24 h, but there, mainly 177 
simple phenolic substances were investigated. Due to the assumption that the 178 
microorganisms need longer for the degradation process of complex phenolic 179 
compounds the fermentation period was extended to 48 h. 180 
Sample preparation and HPLC-ESI-MS/MS analysis for quantification. The 181 
substrates and their metabolites were extracted with ethyl acetate from 400 µL of the 182 
fermentation mixture from every time point. The sample preparation and extraction 183 
were carried out according to Vollmer, Schröter, Esders, Farquharson, Neugart, 184 
Duncan, Schreiner, Louis, Maul and Rohn 28. 185 
HPLC analyses of the substrates and their metabolites were performed using a 1260 186 
Infinity Series system from Agilent Technologies Deutschland GmbH & Co. KG 187 
(Waldbronn, Germany). The system consisted of a binary pump, an online-degasser, 188 
an autosampler, and a column oven. The separation of the substances and their 189 
metabolites was carried out using a Kinetex 5 u EVO C18 100 A (150 x 2.1 mm) 190 
column equipped with an EVO C18 pre-column (both from Phenomenex Inc., 191 
Aschaffenburg, Germany). The chromatographic separation took place at 20 °C. The 192 
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mobile phase was 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile 193 
(B) and the following gradient elution was used: 5% B (0-1 min), 11% B (1-2 min), 194 
14% B (2-4 min), 50% B (4-15 min), 95% B (15-18 min), 95% B (18-22 min), 5% B 195 
(22-23 min) and 5% B (23-32 min). The flow rate was set to 300 µL/min and the 196 
injection volume was 5 µL.  197 
For detecting the substrates and their metabolites, mass analyses were performed in 198 
negative ion mode on an API2000 triple quadrupole MS/MS system (AB Sciex 199 
Germany GmbH, Darmstadt, Germany) equipped with an ESI interface. The following 200 
mass spectrometer settings were used: electrospray voltage = -4500 V, temperature 201 
= 450 °C, curtain gas = 1.7 bar, ion source gas 1 = 2.1 bar, ion source gas 2 = 5.2 202 
bar and collisions gas = 0.5 bar (all nitrogen). For each substance, the optimum 203 
settings of the declustering potential, entrance potential, collision energy, collision 204 
exit potential, and the characteristic fragments were also determined.  205 
For quantification, an external matrix calibration (0-200 µM) for every donor was used 206 
(Supplementary Table 1). The matrix consisted of the fermentation medium and the 207 
fecal sample. The data obtained were analyzed with the software Analyst® 1.5.2 from 208 
AB Sciex Germany GmbH (Darmstadt, Germany). 209 
Beside the substrates used, the following metabolites were included in the method: 210 
benzoic acid, 4-hydroxybenzoic acid, caffeic acid, p-coumaric acid (p-CA), 3-(3,4-211 
dihydroxyphenyl)propionic acid, 3-(3,4-dihydroxyphenyl)acetic acid, 3,4-212 
dihydroxytoluene, ferulic acid, 3-(3-hydroxyphenyl)propionic acid, 3-(4-213 
hydroxyphenyl)propionic acid (4-HPPA), 3-phenylpropionic acid (3-PPA), 3-214 
hydroxyphenylacetic acid (PAA), 4-hydroxyphenylacetic acid, phenylacetic acid 215 
(PAA), hippuric acid, and kaempferol-3-O-glucoside (K-G).  216 
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Analysis of short chain fatty acids. Determination of short chain fatty acids (SCFA) 217 
including acetate, propionate, butyrate, iso-butyrate, formate, but also of further 218 
organic acids such as lactate, succinate, valerate, and iso-valerate was conducted 219 
with 500 µL of the supernatants from the 48 h samples and from one 0 h sample per 220 
substrate. The sample preparation was based on the method developed by 221 
Richardson, et al. 35 followed by gas chromatography analysis using a Hewlett-222 
Packard gas chromatograph fitted with a fused silica capillary column with helium as 223 
a carrier gas. Calculations were done with external standards, 2-ethylbutyrate was 224 
used as internal standard. The mean of the SCFA concentration resulting from the 225 
fermentations with the different substrates were set in relation to the SCFA 226 
concentration from the ‘control samples I’. 227 
DNA extractions, fluorimetric DNA quantification and qPCR analysis. DNA 228 
extractions were done with 400 µL of the fecal suspension from every donor and with 229 
the cell pellets from the 48 h samples using the FastDNA® spin kit for soil (MP 230 
Biomedicals, Illkirch, France). Extraction, fluorimetric DNA quantification and qPCR 231 
analysis were performed according to the protocol described by Vollmer, Schröter, 232 
Esders, Farquharson, Neugart, Duncan, Schreiner, Louis, Maul and Rohn 28. 233 
Universal primers against total bacteria and specific primers against Bifidobacterium 234 
spp., Bacteroidetes, Ruminococcaceae, Lachnospiraceae, F. prausnitzii, Blautia spp., 235 
and the Roseburia/Eubacterium rectale group, were used.28 236 
Illumina sequencing of 16S rRNA genes. The Illumina sequencing of selected 237 
compounds was performed at the ZIEL – Institute for Food & Health of the TU 238 
Munich with DNA extracts of the fecal suspension from every donor (initial 239 
composition), the 48 h sample of tiliroside from all three donors, and the 48 h 240 
samples of vitexin, vitexin-2’’-O-rhamnoside and kaempferol-3,4’-O-diglucoside-7-O-241 
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rhamnoside from donor A and C. The method details are described in the 242 
supplementary information. 429,958 initial sequence reads were filtered as described 243 
in supplementary information, which resulted in 245,816 final reads (11,698-19,887 244 
per sample). Those were assigned to 151 operational taxonomic units (OTUs) at 245 
97% sequence identity (Supplementary Table 2). Sequencing data generated 246 
during this study are available in the SRA database under SRA accession 247 
SRP117249 at http://www.ncbi.nlm.nih.gov/sra/SRP117249. 248 
Statistical analysis. Statistical analysis was performed to investigate whether 249 
differences in SCFA levels or in the microbiota composition resulting from the 250 
substrate fermentations were significant or not compared to the ‘control samples I’. 251 
For that, data were analyzed using IBM SPSS Statistics 22 (Ehningen, Germany). All 252 
data were tested for normality. With the normal distributed data investigations for 253 
significant differences were carried out with an independent t-test. Non-normal 254 
distributed values were analyzed with the non-parametric MANN-WHITNEY-U-test. For 255 
significance, a confidence level of 95% (p < 0.05) was used. In addition, the qPCR, 256 
SCFA, and sequence data were summarized by Principal Component Analysis 257 
(PCA). All data were standardized before applying PCA. The analysis was performed 258 
in R (R Core Team (2012). R: A language and environment for statistical computing. 259 
R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org). 260 
For correlation analysis between qPCR and sequencing data, OTUs were assigned 261 
to the corresponding qPCR assays based on their taxonomy (Supplementary Table 262 
2). 263 
 264 
 265 
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RESULTS AND DISCUSSION 266 
In the present study, the degradation of selected, structurally related, highly 267 
glycosylated flavonoids were determined in three independent in vitro fermentations 268 
in order to estimate metabolite formation and changes in the microbiota composition. 269 
Here, it was of interest to determine if the gut microbiota is able to convert the more 270 
complex flavonoids to lower molecular metabolites, or if they are not or only partially 271 
degraded. For comparison and as a control, in vitro fermentations with the 272 
corresponding aglycones were also performed.  273 
In vitro fermentations of the flavonol kaempferol and its O-glycosides tiliroside 274 
and kaempferol-3,4’-O-diglucoside-7-O-rhamnoside.  275 
Kaempferol. When starting the fermentation experiments with the comparatively 276 
simple aglycone structure kaempferol (K), there was only a slow degradation by the 277 
fecal sample from donor A. K was still present at 48 h and only small amounts of the 278 
metabolite 3-(4-hydroxyphenyl)propionic acid (4-HPPA) were detected (Table 1). 279 
However, K was fully metabolized by 7 h and 24 h, respectively, with the fecal 280 
sample from donors B and C and 4-HPPA was detected at 7 h at its highest 281 
concentration in both cases. During the fermentation with the fecal sample from 282 
donor B no further metabolites were present after 24 h. By contrast, the metabolite 283 
phenylacetic acid (PAA) was detected in the fermentation with the fecal sample from 284 
donor C. In the HPLC-ESI-MS/MS method used, the detector sensitivity for the 285 
metabolite 3-phenylpropionic acid (3-PPA) and PAA was rather low. It cannot be 286 
judged whether e.g., PAA was only formed to lower amounts by donor B unlike for 287 
the other two donors, because responsible microorganisms are missing or the 288 
amount was simply lower than the limit of detection (LOD) of the method. Therefore, 289 
it is possible that the formation of 3-PPA and PAA could not be detected in the 290 
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fermentation B. Nevertheless, the results obtained are in agreement with results 291 
described in the literature, where mainly 4-hydroxyphenylacetic acid, the precursor 292 
for PAA, which was also detected in the present study, has been described as an 293 
important phenolic metabolite (Figure 2).7, 36 294 
Tiliroside. In all three in vitro fermentation experiments, tiliroside (T) was metabolized 295 
significantly by the gut microbiota. Figure 3 displays its degradation steps and 296 
metabolite formation. The detected metabolites were kaempferol-3-O-glucoside (K-297 
G), kaempferol (K), p-coumaric acid (p-CA), 3-(4-hydroxyphenyl)propionic acid (4-298 
HPPA), and 3-phenylpropionic acid (3-PPA), whereby the latter was not detected in 299 
the fermentation with the fecal sample from donor A. In the fermentations of donor B 300 
and C, the bacteria already cleaved the ester bond between the sugar moiety and p-301 
CA within short time resulting in the formation of K-G at 0 h, immediately after 302 
inoculation with the fecal samples (Table 1, Figure 3). An interaction or breakdown 303 
due to the fermentation media can be excluded, because K-G was not detected in 304 
the ‘control samples II’ (substrate + medium, data not shown). The detection of K-G 305 
leads to the assumption that the microbiota did not mainly first cleave the bond 306 
between the kaempferol-moiety and the sugar substituent in T, and T is mostly 307 
degraded to its aglycone K via the intermediate product K-G. However, the 308 
metabolite K-G was only detected in very low concentrations in fermentation A at 0 h, 309 
3 h, and 7 h. Instead, a significant increase of K and p-CA was present within the first 310 
7 h. This may be due to the cleavage of the bond between K and glucose and the 311 
release of p-CA taking place at the same time intervals. Subsequently, the aglycone 312 
was transformed to smaller phenolic acids deriving from the A- and B-ring during the 313 
breakdown of the heterocyclic flavonoid C-ring.25 Furthermore, the microbiota seems 314 
also to be able to use the free p-CA as a substrateas already described in some 315 
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studies where different strains were able to convert p-CA. As a result, further small 316 
metabolites such as 4-HPPA are formed (Figure 2).37, 38 Therefore, the formation of 317 
4-HPPA derives from the degradation of the aglycone structure and p-CA, being a 318 
structural part in the chemical structure T. 319 
While K was metabolized only slowly in the fermentation of T with the fecal sample 320 
from donor A and was still present in a very high concentration at 48 h, p-CA was 321 
degraded continuously up to 24 h. This resulted in the formation of 4-HPPA 322 
corresponding to the reduction of the double bond, which is a very typical reaction in 323 
the microbial transformation of cinnamic acid derivatives.39 At 48 h, 4-HPPA showed 324 
a similar concentration compared to the 24 h samples indicating that no significant 325 
further degradation of 4-HPPA was carried out by the microbiota from the fecal 326 
sample of donor A. In the fermentations with the fecal samples from donors B and C, 327 
4-HPPA was already detected at 7 h at its highest concentration. Subsequently, 4-328 
HPPA was fully metabolized to 3-PPA by a dehydroxylation at the C4-position. This is 329 
in accordance with a study published by Scheline 40, who found that the reduction of 330 
the double bond by fecal microorganisms greatly exceeds dehydroxylation reactions. 331 
Differences between the fermentations B and C can be found in the concentration of 332 
the intermediary metabolites p-CA and 4-HPPA. Both had their concentration 333 
maximum at 7 h. While the concentration of p-CA in fermentation B was much lower 334 
than the concentration of 4-HPPA, the concentration of both metabolites was almost 335 
identical in fermentation C. It is well known, that many anaerobic bacteria are not 336 
able to carry out every degradation step and therefore metabolize aromatic 337 
compounds not completely.19 Consequently, it might be possible that the microbiota 338 
composition of donor B was better adapted for carrying out reduction reactions than 339 
the microbiota of donor C. 340 
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Taking the results of the in vitro degradation of the reference compound K into 341 
account (Table 1), only 4-HPPA and PAA were detected. Therefore, it can be 342 
assumed that p-CA in the fermentations with T was mainly detected because of being 343 
a structural part of T. As already mentioned, p-CA is also the precursor for the 344 
formation of 4-HPPA (Figure 2). Therefore, the amount of 4-HPPA in all 345 
fermentations with T as substrate was much higher than the concentration of 4-HPPA 346 
in the fermentations with the substrate K alone. 347 
Kaempferol-3,4’-O-diglucoside-7-O-rhamnoside. Compared to the fermentation of T, 348 
where several metabolites were identified, a lower number of phenolic metabolites 349 
was determined in the fermentation of the more complex kaempferol-3,4’-O-350 
diglucoside-7-O-rhamnoside (K-DG-R, Table 1). Due to the fact that K-DG-R itself 351 
was not stable in the ion source and therefore, could not be detected with the 352 
analytical method used, the degradation was investigated only by the formation and 353 
degradation of K-G and K. In the ‘control samples II’, where the substrate was 354 
incubated with the medium, neither K-G nor K were detected (data not shown). 355 
Consequently, the formation of the different metabolites resulted only from the 356 
microbial degradation of K-DG-R. For quantification, only the metabolite K-G could be 357 
included in the method, due to the lack of reference compounds. However, 358 
additionally qTOF analyses were carried out and the tentative identification of the 359 
metabolites kaempferol-3,4’-O-diglucoside, kaempferol-3-O-glucoside-7-O-360 
rhamnoside, or kaempferol-4’-O-glucoside-7-O-rhamnoside, and kaempferol-7-O-361 
rhamnoside was possible. The metabolites were detected at the same fermentation 362 
times as K-G (data not shown). Furthermore, the metabolites K-G (0-7 h), K (3-48 h), 363 
and 4-HPPA (48 h) for the fermentation with the fecal sample from donor A and K-G 364 
(0-3 h), K (3 h), and PAA (24-48 h) in the fermentations with the fecal sample from 365 
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donors B and C were detected and quantified. In conclusion, as already shown for 366 
the substrate T, K-DG-R was degraded to phenolic acids via the consecutive release 367 
of the sugar moieties and the aglycone. 368 
In comparison to the reference compound K, similar metabolites were detected. But, 369 
in the fermentation B and C of K-DG-R only the phenolic acid PAA but not the 370 
metabolite 4-HPPA was present compared to the fermentation of K. It is possible that 371 
the formation of PAA went via 4-HPPA which was not detected in the fermentations B 372 
and C, probably resulting from the time intervals, when the samples were taken 373 
(Table 1, Figure 2). 374 
In vitro fermentation of the flavone apigenin and its C-glycosides vitexin, 375 
vitexin-2’’-O-rhamnoside, vitexin-2’’-O-glucoside and vitexin-2’’-O-xyloside. In 376 
the in vitro fermentations of apigenin (AP) and its C-glycosidic derivatives, all three 377 
human fecal microbiomes were able to convert the substrates yielding smaller 378 
phenolic acids. Analogously to the fermentation of the phenolic compounds 379 
mentioned above, differences between the donors in the metabolite formation were 380 
determined. Furthermore, the fermentations with the fecal sample from donors B and 381 
C showed the formation of smaller molecular metabolites than the fermentation with 382 
the fecal sample from donor A. Also, the same metabolites, 4-HPPA, PAA, and 3-383 
PPA were detected, but the intermediate products differed between the initial 384 
substrate. 385 
Apigenin. In the fermentation with the fecal sample from donor A, AP was still 386 
detected at 48 h, while in the fermentation with the fecal sample from donors B and 387 
C, there were only low concentrations of AP at 0 h. Consequently, as AP was not 388 
present in the ‘control samples II’ (data not shown), an interaction between the 389 
substrate and the medium can be excluded, and it appears that it was already 390 
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partially degraded. In general, the formed metabolites were 4-HPPA (A: 24 h, 48 h; B: 391 
7 h, C: 3 h, 7 h) and PAA (A: 48 h; B: 48 h, C: 24 h, 48 h) for all three fermentations 392 
and additionally 3-PPA (B: 24 h, 48 h, C: 24 h, 48 h) for the fermentations with the 393 
fecal sample from donors B and C (Table 2). 394 
Vitexin. The fermentations with the substrate vitexin (V) showed the same phenolic 395 
acid metabolites as the fermentation of AP, with different maxima: 4-HPPA (A: 24 h, 396 
48 h; B: 24 h, 48 h), PAA (A: 48 h; B: 24 h, 48 h, C: 24 h, 48 h), and 3-PPA (B: 24 h, 397 
48 h; C. 24 h, 48 h) (Table 2). V itself was degraded within the first 24 h in the 398 
fermentations with the fecal samples from donors B and C but only disappeared after 399 
48 h in the fermentation with the fecal sample from donor A. Additionally, the 400 
metabolite AP was detected at 48 h in the fermentation with the fecal sample from 401 
donor A. Therefore, the degradation of V seems to take place via the formation of the 402 
aglycone structure and the glucose moiety was primarily cleaved by the bacteria. Due 403 
to faster metabolism, AP was probably not detected in the fermentations with the 404 
fecal samples from donors B and C. The metabolites observed are in agreement with 405 
descriptions in the literature, where for example the rod-shaped Gram-positive 406 
Lachnospiraceae strain CG19-1, was able to convert the substrate V.23 In contrast, 407 
two Lactococcus species and one Enterococcus species were not able to convert V, 408 
as described by Kim, et al. 41 . 409 
Vitexin derivatives. In the fermentations with the different vitexin derivatives, the 410 
concentrations of vitexin-2’’-O-glucoside (V-G), vitexin-2’’-O-rhamnoside (V-R), and 411 
vitexin-2’’-O-xyloside (V-X) were very low or initial substances not even detectable in 412 
the fermentation samples. In contrast to V, those compounds have a second sugar 413 
moiety bound which increases their water solubility. It is assumed that the vitexin 414 
derivatives still remain in the aqueous fermentation medium when extracting the 415 
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substrates and metabolites with ethyl acetate. Due to the fact, that the ‘control 416 
samples II’ (substrate + medium) did not show any phenolic breakdown products and 417 
substrate concentrations in the ‘control samples II’ and fermentation samples were 418 
very similar, the formed metabolites can be attributed to the degradation of the 419 
corresponding initial substances (data not shown). Consequently, the degradation of 420 
the vitexin derivatives could only be displayed by their metabolite formation. 421 
In all in vitro fermentations with the different vitexin derivatives, the degradation went 422 
via the intermediate product V indicating that the first step was cleavage of the O-423 
glycoside bond by the microbiota. On the basis of the formation of V, it was possible 424 
to compare the release of the second glycoside moiety. It can be seen that in 425 
fermentation B and C  the release of the glucose moiety was quicker than the release 426 
of rhamnose, or xylose (Table 2). Figure 4 shows exemplarily the V formation within 427 
the in vitro fermentation with the fecal sample from donor B for the three different 428 
vitexin derivatives investigated. Graphs were normalized to 100%. This effect may be 429 
due to the fact that glucoside units are more common in nature and more 430 
microorganisms are adapted to utilize glucose linked to secondary plant phenolics 431 
than other sugars.42 Despite the intermediate metabolite V, the main end products of 432 
the fermentation of the vitexin derivatives were 4-HPPA, PAA, and only 3-PPA in one 433 
case, which is in accordance with the metabolites resulting from the degradation of V 434 
(Table 2). 435 
The aglycone AP was not detected in the fermentations of the different vitexin 436 
derivatives, but similar metabolites were detected compared to the fermentation of 437 
pure AP (Table 2). Due to the fact, that the metabolite V was present and V itself 438 
appears to be degraded to phenolic acids via the intermediate product AP, it was 439 
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assumed that the formation of the phenolic acids went via the aglycone structure as 440 
well. However, this was not detectable in the present study. 441 
It is recognizable that the recovery rates of the initial substrates in some 442 
fermentations (i. e., V-G) were very low compared to the amount of the phenolic 443 
substrates in the fermentation mixture. When looking at the ‘control samples II’, 444 
where the phenolic compounds were co-incubated with the medium, it is notably that 445 
the concentrations of the phenolic compounds were not higher and very similar 446 
compared to the ones in the fermentation mixtures (data not shown). Therefore, one 447 
possible reason for the low concentrations is interactions between the compounds 448 
and the medium. It is also possible that the compounds precipitate or are adsorbed 449 
without metabolism by the microbial biomass, the solid components of the media or 450 
the inoculum. Furthermore, due to their different hydrophilicity, it is possible that more 451 
hydrophilic substrates still remain in the aqueous medium when extracting with ethyl 452 
acetate.  453 
Before starting the fermentation experiments, different extraction procedures were 454 
investigated and optimized for an overall mixture of compounds in buffered aqueous 455 
media, similar to the one used in the present study, by looking at the recovery rates 456 
after the extraction (data not shown). Due to the fact that the substrates and 457 
metabolites used in this study show very different polarities and solubilities the 458 
methodological approach was a compromise for covering substrates (comparatively 459 
more hydrophobic) and metabolites (comparatively more hydrophilic). 460 
qPCR analysis, Illumina sequencing and SCFA production. Overall microbiota 461 
composition and activity after 48 h of incubation were assessed by qPCR for different 462 
bacterial groups (total bacteria, Bifidobacterium spp., Bacteroidetes, 463 
Ruminococcaceae, Lachnospiraceae, F. prausnitzii, Blautia spp., and the 464 
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Roseburia/Eubacterium rectale group) and determination of short chain fatty acid 465 
production in order to investigate a possible effect of the phenolic substrates on the 466 
microbiota. Significant differences (p < 0.05) between the ‘control samples I’ (medium 467 
+ fecal sample without any substrate) and the different fermentations after 48 h of 468 
incubation were not determined for any of the bacterial groups or SCFA 469 
(Supplementary Table 3). The PCA (Figure 5) based on the relative qPCR and 470 
SCFA results shows that the different samples, even after 48 h of incubation, 471 
clustered by donor and not by the different phenolic substrates used. Therefore, the 472 
different phenolic compounds did not have a major effect on the microbiota. 473 
Furthermore, it is assumed that the SCFA in this study were mainly formed from the 474 
carbohydrates present in the fermentation media and fermenting the sugar moiety of 475 
the flavonoid glycosides did not lead to a significant difference because of the quite 476 
low concentrations of these compounds in the fermentation mixture. 477 
Additionally, Illumina sequencing was performed with selected samples to investigate 478 
whether specific bacteria were affected by the presence of the phenolic substrates 479 
that may not have been detected by the qPCR analysis. Correlation between qPCR 480 
data and corresponding sequence data overall showed good agreement 481 
(Supplementary Figure 1). Small variations are likely due to slight differences in 482 
qPCR primer specificity and the presence of un- or misassigned sequences in the 483 
sequencing data. Figure 6 shows the results of the Illumina sequencing at genus 484 
level. The distribution on the phylum and family level is displayed in the supporting 485 
information (Supplementary Figures 2 and 3).  486 
When looking at the microbiota composition, it is recognizable that the composition of 487 
the fecal sample from donors B and C were quite similar and in line with a microbiota 488 
composition to be found in healthy humans dominated by Firmicutes and 489 
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Bacteroidetes.43 The composition of the fecal sample from donor A on the other hand 490 
was very different, which was confirmed by PCA at OTU level (97% sequence 491 
identity, Supplementary Figure 4). In particular, it had a very high abundance of 492 
Firmicutes, but low Bacteroidetes (Supplementary Figure 2). This initial fecal 493 
sample also showed the biggest change in microbiota composition investigated by 494 
Illumina sequencing after 48 h of incubation with all substrates (Supplementary 495 
Figure 4), with a big increase in Bacteroidetes and Proteobacteria at the expense of 496 
Firmicutes at the phylum level (Supplementary Figure 2). Only a few genera 497 
showed a major increase in relative abundance after incubation (Bacteroides, 498 
Parabacteroides, Clostridium XIVa, Acidaminococcus, Veillonella, unknown 499 
Burkholderiales and Escherichia/Shigella; Figure 6). Microbiota compositions 500 
between samples that were incubated with different phenolic substrates for 48 h were 501 
very similar within the donors (Figure 6, Supplementary Figure 4). This is in 502 
agreement with the results from the qPCR and SCFA analysis. Usually, α-diversity is 503 
used to express the mean variation of species to be found in a certain microbiome. In 504 
this study, α-diversity was similar in all three fecal samples and remained high after 505 
incubation with the fecal sample from donor C, but was lower after incubation with the 506 
other two donors, particularly with donor A (Supplementary Table 4). β-Diversity 507 
could not be calculated due to the limited number of samples. PCA analysis and a 508 
dendogram were used for a visual presentation (Supplementary Figure 4). 509 
In a study published by Duda-Chodak 43, it was concluded that flavonoid aglycones 510 
may inhibit growth of some intestinal bacteria, consequently leading to a modulation 511 
of the whole intestinal microbiome. Especially in the fermentations with the fecal 512 
sample from donor A, where the microbiota composition changes most between 0 h 513 
and 48 h, the aglycone was always present for longer than in the fermentations with 514 
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the fecal sample from donors B and C. Consequently, it might be possible that this is 515 
a reason for the bigger differences. However, qPCR and SCFA data (Figure 5) 516 
indicate that the control samples without phenolic substances had a similar 517 
microbiota composition and activity. The incubations of fecal microbiota from donor A 518 
showed a microbiota shift that may indicate exposure to oxygen as oxygen tolerant 519 
bacteria were stimulated (in particular Escherichia/Shigella). While this is principally 520 
possible, there was no indication that this actually happened in the corresponding 521 
incubations. Anaerobic conditions were checked with the addition of resazurin (0.1%) 522 
to the fermentation media. Resazurin is a redox indicator that changes from colorless 523 
via pink into blue when oxygen is present. In all three fermentations no color change 524 
was detected, suggesting that the microbiota shift seen was due to unusual initial 525 
composition of fecal sample A rather than an experimental mistake. 526 
For decades, it is controversially discussed that manipulation of the composition by 527 
prebiotics might help to improve health.44 A high amount of bifidobacteria in the gut is 528 
often associated with health promoting effects. In a review published by Duenas, 529 
Munoz-Gonzalez, Cueva, Jimenez-Giron, Sanchez-Patan, Santos-Buelga, Moreno-530 
Arribas and Bartolome 24 studies are described, where a stimulation of the growth of 531 
beneficial bacteria, such as bifidobacteria, was caused by polyphenols, thus, exerting 532 
prebiotic-like effects. In the present study, an increase in the amount of bifidobacteria 533 
between the initial fecal samples and the fermentation samples after 48 h were 534 
detected for nearly all substrates tested. However, a significant difference of the 535 
amount of bifidobacteria between the ‘control samples I’ and the fermentation 536 
samples based on the qPCR results were not detected (Supplementary Table 3). 537 
So, changes are probably caused by the fermentation media or reaction conditions.  538 
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During the fermentation of carbohydrates, where SCFA often result as main products, 539 
specific gases are produced, as well. In this context, it could be also possible to 540 
cluster the bacteria based on their gas release depending on the specific 541 
glycosylated phenolic compounds. For that purpose, gas sensing is an alternative 542 
technology for measuring gases from in vitro fecal sample fermentation.45 However, 543 
this was not possible to test within this study. 544 
Interindividual comparison of the phenolic conversion rates of the different 545 
donors. For all substrates tested, phenolic conversion rate of donor A was slower 546 
than the fermentation rates with fecal samples of donors B and C, which were in turn 547 
quite similar. For evaluating kinetics of the degradation, D50 (degradation50) values of 548 
all substrates were used. These represent the time point, when 50% of the substrate 549 
was totally degraded by the gut microbiota (Tables 1 and 2). It was not possible to 550 
estimate such values for the metabolites, because their formation and a possible 551 
follow-up degradation of a metabolite can take place in parallel. In general, 552 
deglycosylation reactions occurred more quickly than the breakdown of the aglycone 553 
structures. Consequently, based on the conversion rates, the metabolite profiles and 554 
the corresponding time courses differed between the different donors and 555 
fermentations, with the fecal samples from donor A showing in general less 556 
metabolites. These differences are probably caused by the individual microbial 557 
compositions in the microbiota from each donor. In the study published by Justesen, 558 
Arrigoni, Larsen and Amado 34, a major decrease of rutin was observed at first after 8 559 
h of incubation. They concluded that it might be possible that other compounds being 560 
in the media or feces are more preferred substrates (such as carbohydrates) and are 561 
easier to ferment for the bacteria and thus, that the microorganisms probably needed 562 
an adaptation period. Moreover, Cassidy and Minihane 46 describe wide 563 
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interindividual variability in the bioconversion of flavonoids being attributed to specific 564 
enterotypes, suggesting that individuals may be either weak or strong flavonoid 565 
converters. 566 
When comparing the composition of the microbiota after 48 h of incubation with the 567 
substrate T in the present study, it is noticeably that Firmicutes were more dominant 568 
in the fecal sample from donor B and C. In conjunction with above, the microbial 569 
profile of the fermentation A showed more members of the Escherichia/Shigella 570 
cluster (Figure 6). So far, more strains from the Firmicutes have been identified to be 571 
responsible for flavonoid conversion than species from Proteobacteria where 572 
Escherichia/Shigella belongs to.18 For example, three Ruminococcaceae species and 573 
different Lachnospiraceae species were described in the mentioned review as being 574 
part of the degradation of some flavonoid structures, whereby the latter were mainly 575 
found to carry out deglycosylation reactions. Looking at the family level of the Illumina 576 
sequencing results of the present study (Supplementary Figure 3), the amount of 577 
Ruminococcaceae and Lachnospiraceae were much higher in donors B and C than 578 
in donor A. Furthermore, some species within the Lachnospiraceae family were also 579 
identified being able to catalyze reduction reactions, e.g., of p-CA.37, 38 The 580 
sequencing data do not allow resolution at species level, but it is possible that donors 581 
B and C carry more bacteria that are able to perform deglycosylations and reduction 582 
reactions and therefore result in a faster conversion rate than donor A. 583 
Comparison of the degradation of C- and O-glycosides by human fecal 584 
microbiota. When comparing the time courses of the deglycosylations of O- and C-585 
glycosides, the present study showed that O-glycosides are metabolized faster than 586 
C-glycosides, while the degradation rates of the two aglycone structures are very 587 
similar within a fermentation  (Tables 1 and 2). Looking at the fermentations of T and 588 
26 
 
V with the fecal sample from donor B, exemplarily, the concentration of the C-589 
glycoside V remained nearly constant up to 7 h and V was then fully metabolized 590 
(Table 2), whereas the O-glycoside T was already totally degraded within the first 7h 591 
(Table 1, Figure 3B). Additionally, with regard to the different vitexin derivatives, it 592 
was shown that the release of the O-glycoside was faster than the degradation of the 593 
intermediate product V, where the sugar is bound C-glycosidically (Table 2). This 594 
may be due to the fact that O-glycosides occur more frequently in the nature than C-595 
glycosides and that microorganisms are more adapted to cleave the C-O-bond 596 
providing more binding energy. Furthermore, it can be assumed that after the 597 
consumption of C- and O-glycosides they reach different areas of the gut due to a 598 
described enhanced stability of C-glycosides over the O-glycosides. Based on the 599 
different prevailing conditions which are found for several intestinal areas, it might be 600 
also possible that C- and O-glycosides in humans are converted by different 601 
microorganisms. Braune and Blaut 23 investigated the potential of the 602 
deglycosylations of different flavonoid C- and O-glycosides by Eubacterium 603 
cellulosolvens which was only able to cleave the C-glycoside bond in two out of 604 
seven compounds tested. In their study, both aglycones were then not further 605 
degraded to phenolic acids. In contrast, the incubation of E. cellulosolvens with six 606 
different O-glycosides showed that the microorganism was able to deglycosylate five 607 
substrates.23  608 
In all in vitro fermentations with the different flavonoid C- and O-glycosides, more 609 
than one degradation step was identified. As a consequence, not only 610 
deglycosylations occurred, but also a transformation of the aglycones to smaller 611 
phenolic compounds took place. It is described in the literature that the hydrolysis of 612 
(flavonoid) glycosides to their aglycones results in potentially more bioactive 613 
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metabolites compared to the initial compounds. However, a further microbial 614 
degradation of the aglycone to smaller metabolites can lead to the formation of more 615 
or less active compounds.47 The fact that microorganisms are often not able to carry 616 
out all degradation steps was already described for the small phenolic acid caffeic 617 
acid by Peppercorn and Goldman 48, in 1971. This seems to be valid for the 618 
degradation of flavonoids as well. For example, in the study published by Braune and 619 
Blaut 23, E. cellulosolvens was only able to carry out deglycosylation reactions, 620 
resulting in the aglycone structure as the only metabolite. However, in the substrates 621 
metabolized by E. cellulosolvens, the glucose moiety was bound at the C6-position. 622 
When glucose was present at the C8-position (e.g., vitexin) degradation did not 623 
occur. Braune and Blaut further showed that the intestinal Lachnospiraceae strain 624 
CG19-1, in contrast to E. cellulosolvens, was able to convert six out of the seven 625 
tested C-glycosides via the aglycone structure to small phenolic acids, indicating 626 
deglycosylation, ring fission, and dehydroxylation reactions.23 Investigations done by 627 
Nakamura, et al. 49 on the cleavage of the C-glycosyl bond of puerarin (an isoflavone 628 
glucoside) by a strain called PUE showed only a conversion to its aglycone daidzein. 629 
Smaller phenolic acids were not detected.49 In this context, it is not clear whether the 630 
degradation steps of the substrates used in the present study are carried out by only 631 
one or even more microorganisms. 632 
In summary, all substrates used in the present in vitro study were converted yielding 633 
lower molecular weight phenolic acids. Deglycosylation reactions were carried out by 634 
the microbiota first, followed by the further breakdown of the aglycone structure. 635 
Comparing the donors with each other, similar metabolites were detected, even 636 
though different time courses for metabolite formation were observed. With regard to 637 
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the microbial composition or activity (SCFA), an influence of the flavonoid glycosides 638 
was not detected.  639 
When looking at the results of the present study, the degradation of the selected 640 
phenolic compounds showed more or less the same course of degradation that 641 
resulted in very similar metabolite profiles, as well. Only the fermentation rates were 642 
different. Therefore, we did not expect very different degradation pathways and more 643 
outcomes when fermenting the substrates with fecal samples of additional 644 
volunteers. The degradation pathways might only be significantly different, when 645 
using fecal samples of volunteers having a known disorder (e.g., by taking antibiotics) 646 
or significantly different dietary habits. It is known that one donor of the present study 647 
was a vegetarian, but significant differences in metabolite formation were not 648 
detected, at all. Also, seasonable differences might be possible, too, but the main aim 649 
of the study was to monitor the degradation profile with regard to the (complex) 650 
phenolic compounds selected. Therefore, more fermentations with more fecal 651 
samples were not carried out. When comparing with in vitro fermentation experiments 652 
described in the literature it is obvious that the use of one to four different fecal 653 
samples is usual.21, 29-31  654 
In conclusion, flavonoid glycosides can be metabolized by the human gut 655 
microorganisms when consumed in concentrations found in typical diets (~20 656 
mg/day), but a prebiotic effect of the phenolic compounds seems not to be 657 
achievable. However, in a review by Etxeberria, et al. 50, in vitro and in vivo studies 658 
are described which showed an influence of phenolic compounds on the microbiota 659 
composition. The effects were often only significant when the concentrations were 660 
artificially high. This does not mean that a certain influence of the microbiome is not 661 
possible, as not all species present in the gut can be analyzed comprehensively to 662 
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date. But, it is also possible that a substrate on its own is not able to influence the gut 663 
microbiota and the described effects on the microbiota composition are a result of the 664 
interaction of different phenolic compounds and other food components being 665 
present in the food matrix such as proteins. Besides other research groups, Ozdal, et 666 
al. 51 described that a polyphenol-protein interaction results in changes in the 667 
structural, functional, and nutritional properties of both compounds. This interaction is 668 
influenced by several parameters such as pH, temperature, and the chemical 669 
structure of the compounds. Therefore, interactive effects of the polyphenols with 670 
further compounds might influence their metabolism by the microbiota to the 671 
individual strength/binding mechanism of the polyphenol-protein interaction, when 672 
consuming whole foods. 673 
Microbial transformation products might affect microbial composition and might 674 
therefore lead to different consequences for the host and its health.21, 52 Such an 675 
effect could be more pronounced after consumption of C-glycosides, as their slower 676 
cleavage leads to a prolonged exposure to the intact flavonoid. Moreover, an impact 677 
on deeper regions of the colon seems to be possible due to the enhanced stability. 678 
With regard to diversity, it can be hypothesized that the more complex the substrates 679 
(for gastrointestinal fermentation) are, more different metabolites can be formed likely 680 
resulting in a higher variation of gut microbial composition. Although this research 681 
topic is now studied for more than two decades, a final proof of a health-beneficial 682 
effect of isolated phenolic compounds is still missing. In the future, research has to 683 
be extended towards synergisms/interactions with other food compounds and all 684 
what we would call food matrix. 685 
 686 
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Abbreviations. AP, apigenin; p-CA, p-coumaric acid; 4-HPPA, 3-(4-687 
hydroxyphenyl)propionic acid; K, kaempferol; K-DG-R, kaempferol-3,4’-O-688 
diglucoside-7-O-rhamnoside; K-G, kaempferol-3-O-glucoside; LOD, limit of detection; 689 
PAA, phenylacetic acid; PCA, Principal Component Analysis; 3-PPA, 3-690 
phenylpropionic acid; SCFA, short chain fatty acids; T, tiliroside; V, vitexin; V-G, 691 
vitexin-2’’-O-glucoside; V-R, vitexin-2’’-O-rhamnoside; V-X, vitexin-2’’-O-xyloside. 692 
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TABLES 
Table 1: Concentration of the substrates and metabolites within the in vitro degradation of K, T, and K-DG-R with the three different 
donors (A, B, and C). Data represent the mean and standard deviation of triplicates (D50, time point when 50% of the substrate was 
degraded). 
Compound Donor 
Concentration [µM] D50 
0 h 3 h 7 h 24 h 48 h  
Kaempferol A 232 ± 16.0 201 ± 15.8 179 ± 51.4 170 ± 8.32 34.0 ± 20.7 33 h 32 min  
B 68.9 ± 13.4 61.1 ± 32.9 <LOD <LOD <LOD 4 h 45 min 
C 27.5 ± 5.31 16.9 ± 4.53 8.28 ± 11.8 <LOD <LOD 4 h 28 min 
K metabolites        
4-HPPA A <LOD <LOD <LOD <LOD 32.8 ± 0.0100  
 B <LOD <LOD 19.4* 5.97* <LOD  
 C <LOD <LOD 13.8 ± 5.91** <LOD <LOD  
PAA A <LOD <LOD <LOD <LOD <LOD  
 B <LOD <LOD <LOD <LOD <LOD  
 C <LOD <LOD <LOD 13.7 ± 4.91 21.1 ± 18.6  
Tiliroside A 105 ± 13.2  84.4 ± 6.65 54.6 ± 13.0 <LOD <LOD 7 h 17 min 
 B 183 ± 48.5 125 ± 35.1 <LOD <LOD <LOD 4 h 4 min 
 C 107 ± 52.7 75.7 ± 38.2 <LOD <LOD <LOD 3 h 
T metabolites        
K-G A 5.85 ± 2.41 7.16 ± 0.522 8.91 ± 2.62 <LOD <LOD  
 B 91.4 ± 28.1 22.1 ± 10.5 <LOD <LOD <LOD  
 C 31.7 ± 6.36 16.8 ± 3.82 <LOD <LOD <LOD  
K A 32.3 ± 17.7 95.3 ± 21.2 145 ± 19.9 89.6 ± 0.719 79.4 ± 27.2  
 B 5.24 ± 0.176 39.8 ± 8.89 <LOD <LOD <LOD  
 C 4.53 ± 2.33 8.70 ± 4.45 <LOD <LOD <LOD  
p-CA A 19.5 ± 2.61 31.3 ± 12.2 123 ± 19.5 17.1 ± 24.4 3.02 ± 0.776  
 B 3.97 ± 0.453 5.86 ± 1.46 12.7 ± 8.36 <LOD <LOD  
 C 8.14 ± 1.56 19.4 ± 4.35 49.1 ± 9.71 <LOD <LOD  
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4-HPPA A <LOD <LOD <LOD 123 ± 3.56 121 ± 12.4  
 B <LOD <LOD 99.9 ± 53.2 <LOD <LOD  
 C <LOD <LOD 46.9 ± 19.1 <LOD <LOD  
3-PPA A <LOD <LOD <LOD <LOD <LOD  
 B <LOD <LOD <LOD 27.6 ± 26.8** 5.36 ± 9.28**  
 C <LOD <LOD <LOD 91.8 ± 13.3**  38.0 ± 65.8**   
K-DG-R A <LOD <LOD <LOD <LOD <LOD  
 B <LOD <LOD <LOD <LOD <LOD  
 C <LOD <LOD <LOD <LOD <LOD  
K-DG-R metabolites        
K-G A 8.77 ± 1.94 36.6 ± 13.2 10.3 ± 1.17 <LOD <LOD  
 B 35.8 ± 6.55 88.7 ± 61.2 <LOD <LOD <LOD  
 C 3.92 ± 0.976 30.7 ± 24.9 <LOD <LOD <LOD  
K A 13.0 ± 7.57 131 ± 12.1 170 ± 14.4 151 ± 40.8 6.60 ± 1.65  
 B <LOD 54.9 ± 0.701 <LOD <LOD <LOD  
 C <LOD 13.3 ± 5.25 <LOD <LOD <LOD  
4-HPPA A <LOD <LOD <LOD <LOD 33.5 ± 2.88  
 B <LOD <LOD <LOD <LOD <LOD  
 C <LOD <LOD <LOD <LOD <LOD  
PAA A <LOD <LOD <LOD <LOD <LOD  
 B <LOD <LOD <LOD 21.8 ± 23.4 15.5 ± 19.9  
 C <LOD <LOD <LOD 3.05 ± 7.74 18.3 ± 10.1  
<LOD (limit of detection) 
* the metabolite was only detected in one sample out of the triplicate fermentation 
** the metabolite was only detected in two samples out of the triplicate fermentation  
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Table 2: Concentrations of the substrates and metabolites within the in vitro degradation of AP, V, V-G, V-R and V-X with the three 
different donors (A, B, and C). Data represent the mean and standard deviation of triplicates (D50, time point when 50% of the 
substrate was degraded). 
Compound Donor 
Concentration [µM] D50 
0 h 3 h 7 h 24 h 48 h  
Apigenin A 106 ± 16.0 97.9 ± 7.57 98.6 ± 11.7 65.4 ± 26.9 34.0 ± 20.7 33 h 29 min 
B 22.9 ± 14.5 15.4 ± 3.02 <LOD <LOD <LOD 4 h 35 min 
C 24.1 ± 2.66 25.3 ± 6.55 <LOD <LOD <LOD 5 h 6 min 
AP metabolites        
4-HPPA A <LOD <LOD <LOD 38.7 ± 9.56 173 ± 55.5  
 B <LOD <LOD 187 ± 66.2 <LOD <LOD  
 C <LOD 32.9 ± 18.6 124 ± 7.95 <LOD <LOD  
3-PPA A <LOD <LOD <LOD <LOD <LOD  
 B <LOD <LOD <LOD 8.01 ± 1.55 49.8 ± 35.1  
 C <LOD <LOD <LOD 143 ± 24.1 214 ± 39.4**  
PAA A <LOD <LOD <LOD <LOD 13.8 ± 12.1  
 B <LOD <LOD <LOD <LOD 24.4 ± 21.3  
 C <LOD <LOD <LOD 52.4 ± 14.9 50.4 ± 7.64  
        
Vitexin A 113 ± 23.1 117 ± 27.3 108 ± 11.6 112 ± 1.04 <LOD 35 h 52 min 
 B 147 ± 21.9 96.6 ± 31.1 115 ± 17.8 <LOD <LOD 13 h 8 min 
 C 131 ± 4.53 121* 128 ± 4.85 <LOD <LOD 15 h 17 min 
V metabolites        
AP A <LOD <LOD <LOD <LOD 39.4 ± 30.5  
 B <LOD <LOD <LOD <LOD <LOD  
 C <LOD <LOD <LOD <LOD <LOD  
4-HPPA A <LOD <LOD <LOD 22.6 ± 0.961 102 ± 32.6  
 B <LOD <LOD <LOD 123 ± 6.76 80.2 ± 17.9  
  C <LOD <LOD <LOD <LOD <LOD  
3-PPA A <LOD <LOD <LOD <LOD <LOD  
 B <LOD <LOD <LOD 41.1 ± 27.0** 25.7 ± 4.90*  
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 C <LOD <LOD <LOD 131 ± 30.7 142 ± 35.9  
PAA A <LOD <LOD 6.70* <LOD 10.9 ± 4.79  
 B <LOD <LOD <LOD 43.8 ± 10.2 47.0 ± 10.2  
 C <LOD <LOD <LOD 47.9 ± 19.8 47.3 ± 9.75  
        
Vitexin-glucoside A 1.84 ± 0.342 2.02 ± 0.652 2.34 ± 0.519 1.22 ± 0.765 0.769 ± 0.152 27 h 50 min 
 B 0.500 ± 0.200 <LOD <LOD <LOD <LOD 1 h 29 min 
 C <LOD <LOD <LOD <LOD <LOD - 
V-G metabolites        
V A <LOD 0.351 ± 0.0137 0.714 ± 0.127 1.29 ± 0.612 <LOD  
 B <LOD 7.02 ± 1.01 3.52 ± 2.09  <LOD <LOD  
 C 0.824 ± 0.0560 2.29 ± 0.578 2.45 ± 1.23 <LOD <LOD  
4-HPPA A <LOD <LOD <LOD 25.9* 37.5 ± 14.4**  
 B <LOD <LOD 14.0 ± 3.79** <LOD <LOD  
  C <LOD <LOD <LOD <LOD <LOD  
PAA A <LOD <LOD <LOD <LOD 7.37 ± 1.30**  
 B <LOD <LOD <LOD 38.3 ± 10.0 32.2 ± 3.6  
 C <LOD <LOD .n.d 35.1 ± 29.0 19.6 ± 1.41  
        
Vitexin-rhamnoside A 8.43 ± 0.623 8.95 ± 1.38 12.3 ± 3.46 13.7 ± 1.66 <LOD 36 h 3 min 
 B 12.0 ± 5.17  9.71 ± 0.424 4.65 ± 0.443 <LOD <LOD 5 h 55 min 
 C 5.58 ± 1.43 7.51 ± 1.40 10.3 ± 0.550 <LOD <LOD 15 h 29 min 
V-R metabolites        
V A <LOD <LOD 2.29 ± 0.851 10.7 ± 7.45 <LOD  
 B <LOD 1.65 ± 0.415 68.8 ± 19.8 <LOD <LOD  
 C 0.845 ± 0.154 1.41 ± 0.475 7.82 ± 1.30  0.748 ± 0.063 <LOD  
AP A <LOD <LOD <LOD <LOD 28.2*  
 B <LOD <LOD <LOD <LOD <LOD  
 C <LOD <LOD <LOD 18.8* 16.6*  
4-HPPA A <LOD <LOD <LOD 23.2 ± 0** 130.8 ± 48.1  
 B <LOD <LOD <LOD 230 ± 25.7 169 ± 59.9  
  C <LOD <LOD <LOD 29.2* 18.0*  
3-PPA A <LOD <LOD <LOD <LOD <LOD  
 B <LOD <LOD <LOD <LOD <LOD  
 C <LOD <LOD <LOD <LOD 236*  
PAA A <LOD <LOD 4.84* <LOD 127*  
 B <LOD <LOD <LOD 52.4 ± 7.21 68.6 ± 22.5  
 C <LOD <LOD <LOD 16.0 ± 11.8 41.4 ± 34.2  
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Vitexin-xyloside*** A 3.99 ± 0.934 2.94 ± 0.194 3.88 ± 0.314 <LOD <LOD 15 h 16 min 
 B 3.23 ± 0.962 3.48 ± 0.367 4.62 ± 0.559 <LOD <LOD 15 h 36 min 
 C 1.37 ± 0.336 1.19 ± 0.218 <LOD <LOD <LOD 4 h 39 min 
V-X metabolites        
V A 1.60 ± 0.284  6.20 ± 0.593 14.2 ± 2.05 57.5 ± 5.07 <LOD  
 B <LOD 0.746 ± 0.093 6.96 ± 2.07 <LOD <LOD  
 C 0.949 ± 0.034 2.81 ± 1.03 14.7 ± 5.78 0.710 ± 0.008 <LOD  
4-HPPA A <LOD <LOD <LOD 24.6* 60.9 ± 7.46  
 B <LOD <LOD <LOD 36.8 ± 9.47** 32.7 ± 30.2**  
  C <LOD <LOD <LOD <LOD <LOD  
PAA A <LOD <LOD <LOD <LOD 9.41 ± 2.47  
 B <LOD <LOD <LOD 54.0 ± 10.1 65.4 ± 20.7  
 C <LOD <LOD <LOD 42.2 ± 13.0 38.9 ± 13.3  
<LOD (limit of detection)  
* the metabolite was only detected in one sample out of the triplicate fermentation 
** the metabolite was only detected in two samples out of the triplicate fermentation 
*** Vitexin-xyloside was quantified via Vitexin-rhamnoside 
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